Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

CFDA

- PMLiVE

MHRA approves SFL’s Aumseqa to treat EGFR-mutated lung cancer in adults

Approximately 43,000 people are diagnosed with lung cancer every year in the UK

- PMLiVE

AstraZeneca’s Calquence approved by EC for first-line chronic lymphocytic leukaemia use

An estimated 27,000 cases of the disease were diagnosed in the UK, France, Germany, Spain and Italy in 2024

- PMLiVE

AstraZeneca’s Forxiga recommended by NICE for wider chronic kidney disease use

An estimated 7.2 million people in the UK are living with the progressive condition

- PMLiVE

AstraZeneca receives CHMP recommendation for Imfinzi regimen in bladder cancer

More than 614,000 cases of bladder cancer are diagnosed globally every year

- PMLiVE

Bristol Myers Squibb’s perioperative Opdivo regimen granted EC approval in NSCLC

Up to 55% of patients with non-metastatic NSCLC develop recurrence despite curative resection

- PMLiVE

AstraZeneca shares late-stage results for Airsupra in mild asthma patients

More than ten million asthma exacerbations occur in the US every year

- PMLiVE

AstraZeneca announces positive phase 3 results for Imfinzi in high-risk bladder cancer

Around half of NMIBC patients are classed as being high-risk for disease progression or recurrence

- PMLiVE

AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer

Around one in three patients with early-stage breast cancer are considered high risk

- PMLiVE

AstraZeneca’s Calquence approved by EC for first-line mantle cell lymphoma use

The drug is now the only BTK inhibitor to be approved in the EU for first-line MCL

- PMLiVE

AstraZeneca’s triple-combination COPD therapy shows promise in uncontrolled asthma

Up to 262 million people worldwide are affected by the chronic respiratory disease

- PMLiVE

AstraZeneca’s Calquence regimens recommended by CHMP for chronic lymphocytic leukaemia

It is hoped that the fixed-duration treatments will reduce the risk of adverse events and drug resistance

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in first-line HER2-positive breast cancer

Up to 20% of patients with metastatic breast cancer are affected by HER2-positive disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links